InnoCan Pharma
@innocanpharma.com
InnoCan Pharma is a pharmaceutical company specializing in developing novel therapeutics that harness the unique healing properties of Cannabinoids to improve quality of life. OUR ADVANTAGES Led by a highly-experienced team with a proven track record of success, InnoCan will leverage Israel’s worldleading medical cannabis research community to develop powerful, Cannabinoid-combined, patent-pending formulas. Our outstanding products will be clinically validated by undertaking Post Marketing Surveillance (PMS) studies and combine smart delivery systems to enhance the potency and efficacy of current products for better results. EXPECTED EARLY REVENUES: InnoCan expects to generate early revenues ($30 million in 5 years) from the multi-billion dollar Over The Counter (OTC) market by leveraging the rapid FDA OTC drug monograph process or similar regulatory pathways in Europe and Canada. These regulatory pathways enable InnoCan, in a very short time, to bring to market outstanding new products that combine the huge therapeutic potential of Cannabinoid complex/hemp oil added “excipients” to existing approved OTC drugs. TECHNOLOGY: POWERFUL, PATENT PENDING FORMULAS WITH SMART DELIVERY SYSTEMS InnoCan's products will be highly differentiated within the market through the powerful synergistic effect of the Cannabis-complex Hemp Oil with the active ingredients, combined with our on-demand release delivery system providing improved patient efficacy and compliance. FIRST-LINE PRODUCTS: A LEAP-FORWARD IN DERMATOLOGY TREATMENT DESIGN The companies first products will initially target the multi-billion dollars markets of psoriasis and localized pain , where research shows topical cannabinoid-combined treatments are highly effective, followed by oral hygiene, eczema/ itching, skin support after chemotherapy and women's health. To join the investment opportunity with InnoCan, please contact Iris Bincovich at [email protected].
InnoCan Pharma's Company Logos
InnoCan Pharma's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#68AAE2
Havelock Blue
104, 170, 226
208, 68, 65
54, 25, 0, 11
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#035565
Blue Stone
3, 85, 101
190, 94, 20
97, 16, 0, 60
About InnoCan Pharma
Innocan Pharma is a leading pharmaceutical technology company that specializes in two main segments: Pharmaceuticals and Consumer Wellness. Under the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies using cannabinoids to treat a variety of conditions and improve patients' quality of life. Their research is currently focused on two drug delivery technologies: the LPT CBD-loaded liposome platform for exact dosing and controlled release of CBD, and the CLX CBD-loaded exosomes platform for targeting the central nervous system and addressing inflammation.
In the Consumer Wellness segment, Innocan develops and markets a wide range of self-care products to promote a healthier lifestyle. They have also established a joint venture called BI Sky Global Ltd., which focuses on advanced targeted online sales. The company is led by a highly experienced management and R&D team, including healthcare executive Iris Bincovich, former Teva Israel CEO Ron Mayron, stem cell expert Prof.
Chezy Barenholz, and neuroscience specialist Prof. Daniel Offen. With their cutting-edge technologies and commitment to innovation, Innocan Pharma is dedicated to improving the well-being of individuals and revolutionizing the pharmaceutical industry
Company type
Privately Held
Year founded
2017
Company size
2-10 employees
Related Brands
Tags
CBD drug delivery systems
Non-opioid chronic pain therapeutics
Liposomal injection technology
Animal health pain management
Wellness and personal care
